Harmony Biosciences Holdings, Inc. (HRMY) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-24
How it makes money
WAKIX generated $868.5 million in 2025 revenue as the only non-scheduled narcolepsy treatment, serving an average of 8,500 patients in the final quarter.
It derives all product revenue from WAKIX (pitolisant), a selective H3 receptor antagonist. Unlike stimulants and other narcolepsy treatments, pitolisant is not a DEA-controlled substance, which simplifies the prescribing process for physicians and access for patients.
Earnings are driven by a combination of patient volume and pricing. The company sells to specialty distributors who then supply the drug to narcolepsy patients. Profitability is influenced by the ability to manage the mix of commercial, Medicare, and Medicaid insured patients, for whom the company has secured high levels of formulary access.
What protects it: the moat
It maintains earnings with pitolisant patents and a non-scheduled status that avoids DEA restrictions, securing access for 80% of all insured lives in the United States.
The business is protected by a patent portfolio licensed from Bioprojet, including composition-of-matter and polymorph patents that extend as far as 2044 for newer formulations. Its primary competitive moat is its regulatory status as the only non-scheduled narcolepsy drug, which avoids the abuse potential and administrative burdens associated with Schedule II or III stimulants and oxybates.
Management claims that WAKIX offers a meaningfully differentiated profile because it does not increase dopamine in the brain's reward center and can be used as a monotherapy or concomitantly with other treatments.
What growth costs
It paid a $100.0 million milestone to Bioprojet and invests in registrational trials like TEMPO to expand pitolisant into new indications like Prader-Willi Syndrome.
Growth depends on heavy reinvestment into clinical trials for label expansion and new formulations. It is currently funding the Phase 3 TEMPO study for Prader-Willi Syndrome and the ONSTRIDE registrational trials for a high-dose formulation of pitolisant.
Reinvestment also takes the form of licensing fees and milestone payments to Bioprojet. The company pays tiered royalties ranging from 13% to 24% on net sales, plus a 3% trademark royalty. Additional capital is deployed for acquisitions, such as Epygenix and Zynerba, to build franchises in rare epilepsy and neurobehavioral disorders.
What could damage it
Because it relies on licensed IP from Bioprojet, any termination of these agreements would stop the company from commercializing its only approved product, WAKIX.
The company faces a critical concentration risk as its entire revenue base and clinical pipeline are built on intellectual property licensed from Bioprojet. A material breach of the 2017 or 2022 License and Commercialization Agreements, or a successful challenge to the licensed patents, would allow Bioprojet to terminate the licenses.
Such a termination would result in the immediate loss of the right to develop, manufacture, or sell pitolisant in the United States, effectively ending the company's operations.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.